PODD

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insulet will release its third-quarter earnings next week, and analysts anticipate a double-digit bottom-line growth.

Omnipod Discover launch puts Insulet’s data platform in focus Insulet (PODD) has rolled out Omnipod Discover nationwide in the US, extending a web-based data platform that earlier limited-release users and healthcare professionals had already begun to adopt.

Insulet has seen its share price fall hard over the past year, which puts the focus squarely on whether the current market value still lines up with the cash the business is expected to generate.

Insulet (PODD) recently reworked its financing by replacing $475 million of term loans with new debt at lower interest margins and expanding its revolving credit facility, a move that directly reshapes the balance sheet.

Insulet (NASDAQ:PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.

Insulet has notably underperformed the Medical Devices industry over the past year, but analysts are cautiously optimistic about the stock’s prospects.